Abstract Manuscripts
CDK4/6 and mTOR inhibition in high-grade glioma
This week, the Ivy Brain Tumor Center published a manuscript in the Oxford University Press on behalf of the Society for NeuroOncology. The manuscript was authored by Nader Sanai, MD, Shwetal Mehta, PHD, and Roel G.W. Verhaak, PHD, in collaboration with other Ivy Center team members.
The manuscript illustrates the results of our Phase 0/1 clinical trial combining two targeted drugs ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) in recurrent high-grade glioma patients, aiming to identify brain-penetrant combinations and assess their impact on malignant cell states.